FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2790240024> ?p ?o ?g. }

• W2790240024 endingPage "S473" @default.
• W2790240024 startingPage "S472" @default.
• W2790240024 abstract "Background: Despite significant survival improvements in multiple pediatric malignancies, children with recurrent and/or metastatic osteosarcoma (OS) (Allison/Menendez, Sarcoma, 2012), relapsed neuroblastoma (NB) (London/Matthay, Journal of Clinical Oncology, 2011) and glioblastoma multiforme (GBM) (Knisely/Baerhing, The Lancet, 2009) continue to have dismal outcomes. GD2 is highly expressed in NB, OS and GBM (Woo/Joo, Anat Cell Biol, 2015). Dinutuximab is an anti-GD2 monoclonal antibody that has significantly increased EFS in children with GD2+ neuroblastoma (Yu/Sondel, NEJM, 2010). ALT-803 is a novel IL15 superagonist complex where mutant IL-15N72D is bound to an IL-15RαSu-Fc fusion protein (Xu/Wong, Cancer Res, 2013). ALT-803 has superior immunostimulatory activity, more favorable pharmacokinetics and pharmacodynamics compared to IL-15 (Rhode/Wong 2016), and is currently being tested in several clinical trials. Objective: We hypothesized that the combination of Dinutuximab with ALT-803 will enhance the in vitro cytotoxicity of exPBNK cells against GD2+ OS, NB and GBM. Method: PBMCs were isolated, and expanded them ex vivo with lethally irradiated K562-mbIL21cells (Denman/Lee Plos One, 2012). ExPBNK cells were isolated using Miltenyi NK cell isolation kits as previously described (Chu/Cairo, Can Imm Res, 2015). NK proliferation, NK receptors expression and cytotoxicity were assessed as previously described (Chu/Cairo, Can Imm Res, 2015). ALT-803 was generously provided by Altor BioScience. Dinutuximab (generously provided by United Therapeutics) was used for antibody-dependent cellular cytotoxicity (ADCC) assays. IFN-g and perforin levels were evaluated by ELISA assays. GD2+ OS (U2OS), NB (SKNF2) and GBM (M059K) cell lines were used as target cells. Results: ALT-803 significantly promoted in vitro proliferation of exPBNK by increasing the phosphorylation of Akt, Stat3/5 and p38 MAPK. ALT-803 also increased the expression of NK activating receptors: NKG2D, NKp30, NKp44, and NKp46. ALT-803 significantly enhanced exPBNK in vivo persistence (P < .05) and significantly reduced tumor burden in OS xenografted mice when combined with exPBNK cells (P < .05). Furthermore, ALT-803 significantly enhanced exPBNK mediated ADCC with dinutuximab against OS, NB and GBM cells in a E:T dependent manner (P < .001) (Figure 1). ALT-803 significantly enhanced IFN-g (P < .001) and perforin (P < .001) release from exPBNK when it was combined with dinutuximab against OS, NB and GBM cells compared to exPBNK, ALT-803 + exPBNK, or dinutuximab + exPBNK. Conclusions: These results show that combining Dinutuximab with ALT-803 significantly enhanced exPBNK ADCC, and IFN-g and perforin release against GD2+ OS, NB and GBM cells. Future studies using NOD/SCID human solid tumor xenograft mouse model are being planned to investigate the in vivo efficacy of this combination." @default.
• W2790240024 created "2018-03-29" @default.
• W2790240024 creator A5001697191 @default.
• W2790240024 creator A5012115728 @default.
• W2790240024 creator A5017266140 @default.
• W2790240024 creator A5020163280 @default.
• W2790240024 creator A5069160791 @default.
• W2790240024 creator A5078245032 @default.
• W2790240024 creator A5086302165 @default.
• W2790240024 date "2018-03-01" @default.
• W2790240024 modified "2023-09-23" @default.
• W2790240024 title "Combining Dinutuximab with ALT-803 (IL-15 Superagonist) Significantly Improves the Activity of Ex Vivo Expanded Natural Killer Cells Against GD2+ Pediatric Solid Tumors (ST)" @default.
• W2790240024 doi "https://doi.org/10.1016/j.bbmt.2017.12.555" @default.
• W2790240024 hasPublicationYear "2018" @default.
• W2790240024 type Work @default.
• W2790240024 sameAs 2790240024 @default.
• W2790240024 citedByCount "0" @default.
• W2790240024 crossrefType "journal-article" @default.
• W2790240024 hasAuthorship W2790240024A5001697191 @default.
• W2790240024 hasAuthorship W2790240024A5012115728 @default.
• W2790240024 hasAuthorship W2790240024A5017266140 @default.
• W2790240024 hasAuthorship W2790240024A5020163280 @default.
• W2790240024 hasAuthorship W2790240024A5069160791 @default.
• W2790240024 hasAuthorship W2790240024A5078245032 @default.
• W2790240024 hasAuthorship W2790240024A5086302165 @default.
• W2790240024 hasBestOaLocation W27902400241 @default.
• W2790240024 hasConcept C109316439 @default.
• W2790240024 hasConcept C150903083 @default.
• W2790240024 hasConcept C159654299 @default.
• W2790240024 hasConcept C167672396 @default.
• W2790240024 hasConcept C202751555 @default.
• W2790240024 hasConcept C203014093 @default.
• W2790240024 hasConcept C207001950 @default.
• W2790240024 hasConcept C26291073 @default.
• W2790240024 hasConcept C2776062744 @default.
• W2790240024 hasConcept C2776715637 @default.
• W2790240024 hasConcept C2778867473 @default.
• W2790240024 hasConcept C40677261 @default.
• W2790240024 hasConcept C502942594 @default.
• W2790240024 hasConcept C542903549 @default.
• W2790240024 hasConcept C54355233 @default.
• W2790240024 hasConcept C55493867 @default.
• W2790240024 hasConcept C71924100 @default.
• W2790240024 hasConcept C81885089 @default.
• W2790240024 hasConcept C86803240 @default.
• W2790240024 hasConcept C8891405 @default.
• W2790240024 hasConcept C98274493 @default.
• W2790240024 hasConceptScore W2790240024C109316439 @default.
• W2790240024 hasConceptScore W2790240024C150903083 @default.
• W2790240024 hasConceptScore W2790240024C159654299 @default.
• W2790240024 hasConceptScore W2790240024C167672396 @default.
• W2790240024 hasConceptScore W2790240024C202751555 @default.
• W2790240024 hasConceptScore W2790240024C203014093 @default.
• W2790240024 hasConceptScore W2790240024C207001950 @default.
• W2790240024 hasConceptScore W2790240024C26291073 @default.
• W2790240024 hasConceptScore W2790240024C2776062744 @default.
• W2790240024 hasConceptScore W2790240024C2776715637 @default.
• W2790240024 hasConceptScore W2790240024C2778867473 @default.
• W2790240024 hasConceptScore W2790240024C40677261 @default.
• W2790240024 hasConceptScore W2790240024C502942594 @default.
• W2790240024 hasConceptScore W2790240024C542903549 @default.
• W2790240024 hasConceptScore W2790240024C54355233 @default.
• W2790240024 hasConceptScore W2790240024C55493867 @default.
• W2790240024 hasConceptScore W2790240024C71924100 @default.
• W2790240024 hasConceptScore W2790240024C81885089 @default.
• W2790240024 hasConceptScore W2790240024C86803240 @default.
• W2790240024 hasConceptScore W2790240024C8891405 @default.
• W2790240024 hasConceptScore W2790240024C98274493 @default.
• W2790240024 hasIssue "3" @default.
• W2790240024 hasLocation W27902400241 @default.
• W2790240024 hasOpenAccess W2790240024 @default.
• W2790240024 hasPrimaryLocation W27902400241 @default.
• W2790240024 hasRelatedWork W2061223989 @default.
• W2790240024 hasRelatedWork W2067077431 @default.
• W2790240024 hasRelatedWork W2122854061 @default.
• W2790240024 hasRelatedWork W2138147234 @default.
• W2790240024 hasRelatedWork W2347673532 @default.
• W2790240024 hasRelatedWork W2416964709 @default.
• W2790240024 hasRelatedWork W2443772760 @default.
• W2790240024 hasRelatedWork W2542718006 @default.
• W2790240024 hasRelatedWork W2975476256 @default.
• W2790240024 hasRelatedWork W2979373204 @default.
• W2790240024 hasVolume "24" @default.
• W2790240024 isParatext "false" @default.
• W2790240024 isRetracted "false" @default.
• W2790240024 magId "2790240024" @default.
• W2790240024 workType "article" @default.